Dr. Douglas R. Adkins, MD

Dr. Adkins practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Adkins' NPI, 1164440616, was assigned on July 17, 2006. Dr. Adkins graduated from Wright State University Boonshoft School of Medicine in 1986. Dr. Adkins holds Missouri license 101986.

Dr. Adkins' primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Adkins also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Adkins' primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Adkins is also affiliated with Missouri Baptist Medical Center. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Adkins to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Adkins practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Adkins' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Adkins is licensed in Missouri.

CMS data shows 1,666 Medicare services from Dr. Adkins across 17 procedure codes in 2024, for 257 Medicare patients. Medicare paid $60,914 for them. Every service was in an office.

CMS counts 257 Medicare patients who saw Dr. Adkins in 2024. The largest group is 65 to 74, with 141 patients. 71% of them have high blood pressure, and 63% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Adkins' median patient age at 70, with 35% women.

In 2024, Dr. Adkins wrote 790 Medicare Part D claims for 92 patients. 79% of them were for generic drugs. CMS names the drug for 620 of them, across 19 drugs with 11 or more claims each, at $978,698 in total drug cost. In 2023, CMS named 649 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Adkins for performance year 2024, reported as part of a group. Dr. Adkins accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Adkins in 2025. 2025 was the busiest year, with 7. The most frequent topics are Squamous Cell Carcinoma of Head and Neck and Head and Neck Neoplasms. Dr. Adkins has published most often in JCO Oncol Pract. Dr. Adkins' most frequent co-authors are Floyd Christopher Holsinger, MD, Ryan Jeffrey Li, MD and Sue Sun Yom, MD, PhD.

CMS Open Payments shows 200 general payments to Dr. Adkins from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 77% of the total. Merck Sharp & Dohme Corporation paid the most, $73,491. It also lists 5 research payments totaling $12,753 from 2020 to 2024.

Dr. Adkins graduated from Wright State University Boonshoft School of Medicine in 1986.